VIVES is a multi-sector fund that invests in projects with a positive societal impact
ExeVir is a clinical-stage company developing antiviral therapies using its VHH technology platform to provide broad protection against viral infections, including coronaviruses. The platform builds...
GreenWatt, founded in Belgium in 2004 as a spin-off from the Catholic University of Louvain (UCLouvain), designs, develops and markets locally integrated "key-to-door" biogas plants for the food and...
Botalys has developed a vertical farming technology that enables the production of rare plants and high-value ingredients for the food supplement, cosmetics, and pharmaceutical industries. This...
Pierre Drion, business angel:
"For almost 20 years I have been passionate about what is called BioTech. This led me to invest in several companies and mainly university spin-offs. In this context, I...
Georges Caron, past CEO Keemotion:
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with the...
Torsten Mummenbrauer, CEO Exevir Bio:
"It has been great to partner early on with VIVES fund. VIVES fund helped us to finance the company, challenged us in our thinking to push us further in our...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is